Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Acorda Therapeutics Inc (ACOR)’s Shares Jump After Dismissal Of Patent Challenge From Hedge Fund Manager Kyle Bass

Among the hedge funds that we track at Insider Monkey, Adage Capital Management, led by Phill Gross and Robert Atchinson, was the largest shareholder of the company, having 1.00 million shares worth $33.33 million in its portfolio at the end of the second quarter. Partner Fund Management and Baker Bros. Advisors were other primary shareholders of the company, with 817,396 shares and 738,916 shares, respectively. Armistice Capital, led by Steven Boyd, initiated a new position in Acorda Therapeutics Inc (NASDAQ:ACOR) during the second quarter, including 186,000 shares valued at $6.20 million. Dmitry Balyasny‘s Balyasny Asset Management was another investment firm initiating a new position of 113,568 shares of the biopharmaceutical company.

Considering the drop in overall hedge fund holdings, it is safe to say that some hedge funds disposed of their stakes in the company during the second trimester. Highbridge Capital Management, led by Glenn Russell Dubin, and Two Sigma Advisors, led by John Overdeck and David Siegel, were two of them, selling out of their entire stakes in Acorda Therapeutics during the second quarter.

Considering the negative hedge fund sentiment and poor share performance in 2015, we do not recommend investing in Acorda Therapeutics Inc (NASDAQ:ACOR) at the moment, despite its apparent victory over Bass.

Disclosure: None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.